The increased frequency of DKA observed in this subpopulation can be explained by the renal and pancreatic effects of SGLT2-inhibitors that are emphasized in patients in therapy with insulin, since to minimize the risk of hypoglycaemia it is necessary to further decrease the insulin dose. The gene discussed is SLC5A2; the disease is Hypoglycemia.